SLXN•benzinga•
Silexion Therapeutics Announces Preclinical Results For RNAi Candidate SIL204, Showing Potent Efficacy Against KRAS G12D-Driven Pancreatic, Colorectal, And Lung Cancers
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 29, 2025 by benzinga